Zenith Technologies and GE Healthcare Life Sciences strike biopharma alliance
The combined offering is aimed at helping biopharmaceutical manufacturers increase productivity, improve efficiency and reduce costs.
Zenith Technologies and GE Healthcare’s Life Sciences business have announced a collaboration to support biopharmaceutical manufacturing deployment.
As part of the partnership, Zenith Technologies’ methodologies, systems and libraries will be offered as a service to GE Healthcare’s clients in bioprocessing. The combined offering is aimed at helping biopharmaceutical manufacturers increase productivity, improve efficiency and reduce costs.
The two companies will integrate process control systems, manufacturing execution system (MES) solutions and other supporting technologies with GE Healthcare’s start-to-finish technologies and solutions for the biopharmaceutical manufacturing industry.
Jan Makela, general manager at BioProcess GE Healthcare said: "The development of our KUBio modular manufacturing facilities and FlexFactory single-use manufacturing platform was fuelled by the need for customers to deploy biopharmaceutical manufacturing capacity more quickly and at a lower cost.
“Implementing these advanced technology platforms requires automation expertise for which we partner with a number of world class companies. With Zenith Technologies’ expertise in automation integration and customer support, we will be able to offer more choice to customers.”
Brendan O’Regan, founder at Zenith Technologies, said: “This is a significant milestone in our development and ushers in a new era of opportunity for both companies.
“GE offers an unprecedented solution to our pharmaceutical customers to help rapidly deploy capacity and significantly reduce time to market. Combined with our manufacturing software systems and on the ground, global support services, we can help biopharmaceutical manufacturers improve their processes and ultimately increase their competitiveness.”
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...